Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma

by Céline Schilthuizen, Annemiek Broyl, Bronno van der Holt, Yvonne de Knegt, Henk Lokhorst, Pieter Sonneveld
Published 2007-02-01

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Ca...

by Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Monique Minnema, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst, Annemiek Broijl, Pieter Sonneveld
Published 2019-11-01

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

by Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Edo Vellenga, Ellen Meijer, Shulamit Wittebol, Bea C. Tanis, Petra B. Cornelisse, Marian Stevens-Kroef, Gerard M.J. Bos, Pierre W. Wijermans, Henk Lokhorst, Pieter Sonneveld
Published 2016-04-01

The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study

by Suzanne van Dorp, Henrike Resemann, Liane te Boome, Floor Pietersma, Debbie van Baarle, Frits Gmelig-Meyling, Roel de Weger, Eefke Petersen, Monique Minnema, Henk Lokhorst, Saskia Ebeling, Scott J.P. Beijn, Edward F. Knol, Marijke van Dijk, Ellen Meijer, Jürgen Kuball
Published 2011-09-01

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

by Antonio Palumbo, Anders Waage, Cyrille Hulin, Meral Beksac, Sonja Zweegman, Francesca Gay, Peter Gimsing, Xavier Leleu, Pierre Wijermans, Gülsan Sucak, Sara Pezzatti, Gunnar Juliusson, Brigitte Pégourié, Martijn Schaafsma, Monica Galli, Ingemar Turesson, Brigitte Kolb, Bronno van der Holt, Ileana Baldi, Jürgen Rolke, Giovannino Ciccone, Marc Wetterwald, Henk Lokhorst, Mario Boccadoro, Philippe Rodon, Pieter Sonneveld
Published 2013-01-01

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

by Monika Engelhardt, Evangelos Terpos, Martina Kleber, Francesca Gay, Ralph Wäsch, Gareth Morgan, Michele Cavo, Niels van de Donk, Andreas Beilhack, Benedetto Bruno, Hans Erik Johnsen, Roman Hajek, Christoph Driessen, Heinz Ludwig, Meral Beksac, Mario Boccadoro, Christian Straka, Sara Brighen, Martin Gramatzki, Alessandra Larocca, Henk Lokhorst, Valeria Magarotto, Fortunato Morabito, Meletios A. Dimopoulos, Hermann Einsele, Pieter Sonneveld, Antonio Palumbo
Published 2014-02-01

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

by Laurens E. Franssen, Inger S. Nijhof, Suzana Couto, Mark-David Levin, Gerard M.J. Bos, Annemiek Broijl, Saskia K. Klein, Yan Ren, Maria Wang, Harry R. Koene, Andries C. Bloem, Aart Beeker, Laura M. Faber, Ellen van der Spek, Reinier Raymakers, Roos J. Leguit, Pieter Sonneveld, Sonja Zweegman, Henk Lokhorst, Tuna Mutis, Anjan Thakurta, Xiaozhong Qian, Niels W.C.J. van de Donk
Published 2018-08-01

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

by Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking Myeloma Multicenter Group (GMMG)
Published 2021-01-01